LncDNAH5 Regulates Radiotherapy-Induced Toxicity via MDM2-Mediated Degradation of TP53BP1 [0.03%]
长链非编码RNA LncDNAH5通过MDM2介导的TP53BP1降解调节放射治疗引起的毒性反应
Xin Sun,Antao Dong,Liangliang Li et al.
Xin Sun et al.
Radiation therapy (RT) cures many patients with localized prostate cancer, but late urinary toxicity impairs quality of life and can limit dose escalation for better RT efficacy. Understanding the mechanistic bases of radiation toxicity is ...
Interobserver Agreement in Acute Toxicity Assessment During Head and Neck Radiotherapy/Chemoradiotherapy: Implications for Endpoint Selection in Clinical Trials [0.03%]
急性毒副反应的组间一致性评价——头颈部放射治疗/放化疗期间的急性毒性评估的组间一致性分析及其在临床试验终点选择中的意义
Shwetabh Sinha,Anuj Kumar,Samarpita Mohanty et al.
Shwetabh Sinha et al.
Background: Acute toxicity is a key endpoint in head and neck radiotherapy (RT) and chemoradiotherapy (CRT) trials and is most commonly reported as maximum toxicity per patient. However, the reproducibility of clinician-r...
Carbon Ion Radiation Therapy of Sacrococcygeal Chordomas: A Comparison of Different Fractionation Schemes [0.03%]
骶尾部节细胞瘤碳离子放射治疗的不同分次方案的比较研究
Hanna Waldsperger,Semi Harrabi,Bastian von Nettelbladt et al.
Hanna Waldsperger et al.
Purpose: Sacrococcygeal chordomas are rare, radioresistant malignant bone tumors that are challenging to treat with conventional photon therapy. Carbon ion radiation therapy (CIRT) offers a favorable dose distribution and...
A phase II randomized trial comparing radiation doses in concurrent chemoradiotherapy with TS-1/nedaplatin for curative treatment of newly diagnosed or recurrent esophageal cancer [0.03%]
卡培他滨联合顺铂同期放化疗治疗新发或复发性食管癌的II期随机对照研究：不同放疗剂量比较
Hideomi Yamashita,Subaru Sawayanagi,Mei Kono et al.
Hideomi Yamashita et al.
Purpose: To evaluate and compare progression-free survival (PFS) between 50.4-Gy and 60-Gy radiation doses in definitive chemoradiotherapy (CRT) for patients with esophageal cancer, and to confirm that the 50.4-Gy is non-...
Acute adverse events of hypofractionated whole-breast radiotherapy with a simultaneous-integrated boost - Results from the randomized controlled HYPOSIB-trial (ARO 2013-05) [0.03%]
超分割序贯加速乳腺癌全乳放疗与同时计划增强照射急性毒性随机对照HYPOSIB试验（ARO 2013-05）结果
David Krug,Reinhard Vonthein,Andreas Schreiber et al.
David Krug et al.
Background: Moderate hypofractionation (HF) is standard of care for adjuvant whole-breast irradiation after breast-conserving surgery (BCS). While boost irradiation has traditionally been administered sequentially (seq) a...
EMPTY-RT: A Phase 2 Trial of Prostate Stereotactic Body Radiotherapy with an Empty Bladder Approach [0.03%]
空膀胱方法前列腺立体定向体放射治疗II期临床研究（EMPTY-RT）
Vedang Murthy,Simran Gulati,Suman Ghosh et al.
Vedang Murthy et al.
Purpose: To evaluate the feasibility and dosimetric safety of prostate stereotactic radiotherapy (SBRT) with an empty bladder approach. Methods: ...
Prospective Evaluation of Novel 4DCT-Ventilation Imaging for Preoperative Risk Assessment in Lung Cancer: Results of the LIME Trial [0.03%]
低剂量CT筛查中肺结节患者术前风险评估的新方法：LIME试验结果的前瞻性分析
Lydia J Wilson,Richard Castillo,Edward Castillo et al.
Lydia J Wilson et al.
Purpose: Surgery is the primary treatment for early-stage lung cancer. Patients with poor preoperative lung function are at increased risk of pulmonary complications after anatomic lung resection. Surgeons determine candi...
Multimodal Contrast-Free Pulmonary Perfusion Imaging by Integrating CT and MRI for Enhanced Lung Function Assessment [0.03%]
基于CT和MRI的对比剂-free多模态肺灌注成像用于增强肺功能评估
Dianlin Hu,Bing Li,Hui Li et al.
Dianlin Hu et al.
Purpose: Anatomy image-driven lung function imaging methods have been explored for thoracic radiotherapy, but most contrast-free approaches rely on unimodal surrogates. This study aimed to develop a multimodal contrast-fr...
Corrigendum to 'A Phase 1b Clinical Trial of Neoadjuvant Radio-immunotherapy for Esophageal Squamous Cell Cancer '[International Journal of Radiation Oncology*Biology*Physics Volume 119, Issue 3, 1 July 2024, Pages 896-901] [0.03%]
食管鳞状细胞癌新辅助放免疫治疗Ⅰb期临床研究的更正说明[国际放射肿瘤学·生物靶向治疗杂志，2024，119(3)：896-901]
Minghao Li,Hongfu Sun,Wenfeng Yang et al.
Minghao Li et al.
Project Optimus for Radiation Therapy-Drug Combinations: Moving Beyond the Maximum Tolerated Dose [0.03%]
辐射治疗-药物组合的优化计划项目：最大耐受剂量之外的探索
Alastair Greystoke,Sarah Brown,Anthony Chalmers et al.
Alastair Greystoke et al.
Purpose: The development of effective radiation therapy (RT)-drug combinations has been slow, largely because early-phase trial designs have mirrored systemic drug development paradigms based on the maximum tolerated dose...